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Nuclearubiquitouscaseinandcyclin-dependentkinasessubstrate(NUCKS)is27kDachromosomalproteinofunknownfunction.
Its amino acid composition as well as structure of its DNA binding domain resembles that of high-mobility group A, HMGA
proteins. HMGA proteins are associated with various malignancies. Since changes in expression of HMGA are considered as
marker of tumor progression, it is possible that similar changes in expression of NUCKS could be useful tool in diagnosis and
prognosis of breast cancer. For identiﬁcation and analysis of NUCKS we used proteomic and histochemical methods. Analysis of
patient-matched samples of normal and breast cancer by mass spectrometry revealed elevated levels of NUCKS in protein extracts
from ductal breast cancers. We elicited speciﬁc antibodies against NUCKS and used them for immunohistochemistry in invasive
ductal carcinoma of breast. We found high expression of NUCKS in 84.3% of cancer cells. We suggest that such overexpression of
NUCKS can play signiﬁcant role in breast cancer biology.
Copyright © 2009 Piotr Zi´ ołkowski et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Nuclearubiquitouscaseinandcyclin-dependentkinasessub-
strate (NUCKS) is a nuclear DNA binding protein occurring
in almost all types of human cells, adult and fetal tissues
[1, 2]. The NUCKS gene is located on human chromosome
1q32.1 and consists of seven exons and six introns. It has
all the features of being a housekeeping gene [2]. Although
its biological function is poorly understood, the structural
similarity to the high-mobility group A (HMGA) proteins
suggests that it plays a role in regulation of chromatin
structureandits activity (fora reviewsee [3,4]).TheHMGA
proteins modulate DNA structure altering transcription of
several genes by either facilitating or impeding binding of
transcription factors [5].
The benign human tumors are mainly of mesenchymal
origin and result from chromosomal rearrangements. These
include lipomas [6, 7], uterine leiomyomas [8, 9], and pul-
monary chondroid hamartomas [10] or tumors consisting of
epithelial and mesenchymal parts like breast ﬁbroadenomas
[11]. Rearrangements and overexpression of the hmgA
genes were described in nonmesenchymal benign human
tumors, such as pituitary adenomas [12]. A high expression
of HMGA proteins was observed in all neoplastic tissues
analyzed including pancreatic, thyroid, colon, breast, lung,
ovarian, uterine cervix and body, prostate, and gastric car-
cinomas (for review see [4]). High levels of HMGA are also
causally related to the neoplastic cell transformation. Finally,
HMGA proteins are also involved in hematological neoplasia
[13]. It was suggested that HMGAs might be promising tar-
gets for therapeutic drugs aimed at alleviating pathological
conditions[14].Itisworthmentioningthatinnormaltissues
HMGA protein level is low or even undetectable. Usually,
high HMGA expression correlates with bad prognostic
factors and metastases. It was assumed that HMGA genes
expression might be used as a marker of tumor progression2 Journal of Biomedicine and Biotechnology
[15]; therefore it can also be considered that NUCKS plays a
similar practical role in histopathological analysis.
The abundance of NUCKS in rapidly growing cells as
well as the overexpression of nucks mRNA in ovarian cancer
[16]suggeststhatitmaybeinvolvedinfacilitatingandmain-
taining activity of transcription of some genes during rapid
proliferationandincancer.UntilnowNUCKSwasstudiedin
detailusingavarietybiochemicalandcellbiologicalmethods
[1, 2, 17–19]. These analyses however do not relate the
occurrence of the protein to histological grade or with a
particular cell type. In this work we analyzed the occurrence
of NUCKS in breast carcinoma. Using proteomic methods
we demonstrated that NUCKS is highly overexpressed in
invasiveductalcancer(IDC).Immunohistochemicalanalysis
conﬁrmed this ﬁnding and also revealed abundant expres-
sionofNUCKSin26casesofthiscancer.Thistypewasfound
to be the most frequent malignant tumor of the breast [20]
and presents very serious therapeutic and socioeconomical
problems. Estimated new cases from breast cancer in the
United States in 2008 were 182460 (female) and 1990
(male) and about 41000 deaths (National Cancer Institute;
http://www.cancer.gov/cancertopics/types/breast).
2.MaterialsandMethods
2.1. Tissues and Protein Extraction. Samples of IDC of grades
II or III were retrieved during surgery. Analysis of the
samples followed an informed consent approved by the local
ethics committee. The entire protein extraction procedure
was carried out as described previously [21]. Brieﬂy, frozen
tissuewashomogenizedwith3vol.(m/v)of5%(v/v)HClO4
using an IKA Ultra Turbax blender and the homogenate
was centrifuged at 15,000×g for 5 minutes. Proteins were
precipitated with 33% (w/v) CCl3COOH for 30minutes and
collected by centrifugation at 15,000×gf o r1 0m i n u t e s .
2.2. SDS-PAGE and Protein Digestion. Aliquots of protein
fractions containing NUCKS were separated by SDS-PAGE,
using NuPAGE Novex Bis-Tris 4%–12% gels (Invitrogen,
Carlsbad, CA, USA) and MES running buﬀer according
to the manufacturer’s instructions. The gel was stained
with Coomassie Blue using Colloidal Blue Staining Kit
(Invitrogen).
The NUCKS bands were subjected to a standard in-
gel trypsin digestion protocol [22]. Brieﬂy, the pieces
were washed twice with 25mM ammonium bicarbonate
and dehydrated with absolute ethanol. Subsequently, 0.5μg
trypsin (Promega, Madison, WI) solution in 25mM ammo-
nium bicarbonate was added, and the enzyme was allowed
to digest overnight at 37◦C. The peptide mixtures were
extracted with 80% CH3CN, 1% CF3COOH (TFA), and
the organic solvent was evaporated in a vacuum centrifuge.
The resulting peptide mixtures were desalted using in-house
made C18 STAGE tips [23], vacuum-dried, and reconstituted
in 0.05% CF3COOH prior to the analysis.
2.3.LC-MS/MSAnalysis. Peptidemixtureswereseparatedby
online reversed-phase nanoscale capillary liquid chromatog-
raphy and analyzed by electrospray tandem mass spectrom-
etry as described previously [24]. The data were searched
against the full International Protein Index (IPI) database
with the aid of the MASCOT (Matrix Science, London,
UK) search engine [25]f o l l o w e db ym a n u a lv e r i ﬁ c a t i o n .A l l
peptides identiﬁed from the NUCKS gel bands are listed
in the Supplementary Table 1 in Supplementary Material
available online at doi:10.115/2009/919645.
2.4. Antibodies. Antibodies against NUCKS were elicited
in rabbits using synthetic peptide DEDYGRDSGPPTKKC
(residues 23–26) conjugated to ovalbumin (Imject Male-
imide Activated Ovalbumin, Pierce). Animals were injected
with 0.2mg of cross-linked peptide. Titer and speciﬁcity of
the antisera were increased by three injections (boosts).
Monospeciﬁc antibodies were puriﬁed on aﬃnity
columns which were prepared by coupling of the peptide
to iodoacetate activated gel (SulfoLink, Pierce) according to
the manufacturer’s protocol using 1mg of the peptide per
1mL of the coupling gel. The unreacted maleimide groups
were quenched with 20mM cysteine. Then 1mL of the gel
was loaded into a column and washed with 50mL PBS.
5mL of the antiserum was diluted with 5mL PBS and
incubated with the gel for 4hour. Following washing of the
gel with 50mL PBS the bound antibodies were eluted with
10mL of 0.1M glycine-HCl, pH 2.5, and after that with
10mL 4M guanidine hydrochloride in PBS. The eluates were
diluted with 10mL of PBS and concentrated in Centriprep-
Ultracel YM-10 (Millipore) concentrators to a volume of
2mL. The concentrates were dialyzed against PBS overnight.
The guanidine hydrochloride fraction of antibodies was used
in all experiments.
2.5. Western Blotting. For Western analysis, proteins were
transferred from SDS gels onto the nitrocellulose membrane
by electroblotting at 10V/cm for 40min. The proteins were
cross-linked to the membrane by incubation in 0.5% (v/v)
glutaraldehyde in PBS for 10min. The membranes were
blockedwith10%(v/v)normalgoatserum(NGS)for30min
prior to incubation with the primary antibodies together
with 1% NGS in PBS containing 0.1% Tween 20 (PBS-T).
The concentration of the primary antibodies was 1.5μg/mL.
Following 2hour incubation, the membrane was extensively
washed with PBS-T. Primary antibodies were visualized on
the membrane with ECL peroxidase-conjugated IgGs. After
the detection of antibodies blots were stained with Amido
Black stain (Sigma, St Louis, MO).
2.6. Histopathology. 26 samples of breast cancer, derived
from 26 diﬀerent female patients, were investigated in
this experiment. In particular, this was the invasive ductal
carcinoma (IDC) of grade (G) I (10 cases), II (6 cases), and
III (10 cases). Cancer was excised during radical mastectomy
or tumorectomy depending on the result of the previously
performed imaging studies, ﬁne-needle aspiration biopsy,
oligobiopsy, or intraoperative diagnosis.
The samples from the tumors were ﬁxed in 4% formalin
a n de m b e d d e di np a r a ﬃn. After that, the paraﬃn blocks
werecutonmicrotometoobtain4μmthicksliceswhichwere
mounted on glass slides and stained with hematoxylin-eosin
(HE) or with antibodies. Evaluation of HE-stained samplesJournal of Biomedicine and Biotechnology 3
wasperformedbyuseoflightmicroscope(OLYMPUSBX50)
at magniﬁcation 100 or 200 times.
2.7.ImmunohistochemicalStaining. Followingdeparaﬃniza-
tion the antigen determinant was retrieved using normal
pressure cooking in 0.01M sodium citrate for 9 minutes in
350W microwave oven at pH 6. The slides were blocked
for endogenous peroxidase (Peroxidase Blocking Reagent,
DAKO Cytomation) and incubated overnight with anti-
NUCKS antibodies at concentration of 15μg/mL in PBS
containing 125-fold diluted swine serumat 4◦C. The binding
of the primary antibodies was visualized using the ABC
method (kit LSAB, DAKO Cytomation) and stained with
DAB (DAKO). The PBS was used on each step. Finally, the
slides were counterstained with hematoxylin and rinsed in
tap water.
Percentageofpositivelystainedcancercellswasevaluated
on 5 ﬁelds from the centre of tumor: number of positively
stained cells (nuclei and cytoplasm) was divided by the total
number of cancer cells seen on that ﬁeld at magniﬁcation
of 400 times. A mean value from 5 such ﬁelds is shown
in “results” section. The selection criterion for the 5 ﬁelds
measuredwasthecentreofeachsampleandthiswasassessed
by two pathologists. We also evaluated staining in other
cells: lymphocytes and endothelial cells used as positive
control because it was suggested that NUCKS is localized in
both proliferating and nonproliferating cells [18]. Negative
control obtained by omitting the primary antibody.
The microphotographs were taken using light micro-
scope (OLYMPUS BX40) at magniﬁcation 200 times and
digital camera DP10. Two independent pathologists eval-
uated each slide. Statistical analysis of correlation between
histological grading and number of positively stained cells
wasmade.ANOVAone-wayanalysisofvariancebyrankswas
used for this statistical analysis.
3. Results
3.1. NUCKS Is Highly Overexpressed in Ductal Invasive
Breast Cancer. A group of nuclear proteins including linker
histones H1 and HMG proteins can be selectively extracted
from cells and tissues with diluted perchloric acid [21].
NUCKS also can quantitatively be extracted using 5%
perchloric acid. To compare the levels of NUCKS in human
cancerandnondiseasedtissuesweextractedtheproteinfrom
ﬁve pairs of matched diseased and normal samples, from 5
patients, and analyzed its abundance on SDS gels. The iden-
tity of the NUCKS-band was analyzed by mass spectrometric
analysis. We found that in each of the ﬁve cases NUCK was
the only abundant component of the stained gel-band. All
identiﬁed peptides with their precursor ion accuracy and
Mascot scores are listed in Supplementary Table 1.
We found that the band of NUCKS with a relative
Mr of 43,000 occurred abundantly in all samples of IDC,
whereas in all normal samples either it did not appear or
the band was very weak (Figure 1). The levels of NUCKS in
IDC were comparable with those in cultured breast cancer
cells MCF7. Since overexpression of NUCKS in ovarian
Table 1: The NUCKS positive staining in cells of invasive ductal
carcinoma (in %) with relation to histological grading (I-II-III).
Grade Number of cases % stained cell (SD)
I 10 77.5 (5.36)
II 6 85.5 (4.59)
III 10 89.6 (3.47)
Total 26 84.3
cancer was recently described [16], we analyzed also ovarian
cancer sample and found similar extent of upregulation
of NUCKS in this type of cancer in comparison to IDC.
From this experiment we concluded that NUCKS is highly
overexpressed in IDC and we decided to study its occurrence
in more detail.
3.2. Generation of Polyclonal Monospeciﬁc Antibodies against
NUCKS. To investigate the occurrence of NUCKS in cells
and tissues, antibodies against a peptide corresponding to
residues 23–36 of the protein were elicited in rabbits and
were aﬃnity puriﬁed. The speciﬁcity of the antibodies was
analyzed on western blots using puriﬁed NUCKS, perchloric
acid extracts and whole SDS wholelysatesof MCF7 cells,and
IDC and normal breast tissue (Figure 2). The blots revealed
thatourantibodiesdecoratedselectivelythebandofNUCKS,
indicating the high speciﬁcity of the antibodies. Western
analyses using other lysates and extracts of human tissue and
cells resulted in identical results (not shown).
3.3. Histochemical Analysis of NUCKS in Invasive Ductal
Carcinoma. The study comprised 26 cases of invasive ductal
carcinoma (IDC). They were ﬁrst evaluated with regard
to histopathology (grading) and then the samples from
particular tumors were studied using immunohistochemical
m e t h o d .T h eo c c u r r e n c eo fN U C K Sw a so b s e r v e di nt u m o r
cells as well as in other cells seen in samples, like endothelia
and lymphocytes.
In invasive ductal carcinoma, IDC (carcinoma ductale
inﬁltrans), the positive staining of cytoplasm was rather less
intensive than that of nuclei (Figure 3, with an inset). The
cytoplasmic staining in IDC cells is shown in Figure 4 (with
an inset). The number of stained cells, both nuclei and
cytoplasm, ranged from 77.5% of cancer cells in group of
grade I (Figure 5) to 89.6% in the group of grade III (mean:
84.3%, for the whole group of 26 cases, see Table 1). A
low number of lymphocytes which formed inﬂammatory
inﬁltration at the border of tumor foci showed positive
nuclearreaction(Figure 6).Positivenuclearreactionwasalso
observed in endothelial cells. Negative control is shown in
Figure 7,whileFigure 8showsfattissuefromtheIDCpatient
at a morphologically normal site away from the lesions
without any immunohistochemical reaction.
Considering the signiﬁcance level, α = 0.05, we can
conﬁrm statistically signiﬁcant diﬀerence between group of
GI cancers and GII (P = .00235) and also between GI
and GIII (P = .000004), whereas there was no signiﬁcant
diﬀerence between groups GII and GIII (P = .0931)
(Figure 9 and Table 2).4 Journal of Biomedicine and Biotechnology
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Figure 1: NUCKS is highly overexpressed in breast cancer. Lanes 2–11: Protein extracts from ﬁve pairs of tissue, each pair matching the
individual patient, of normal breast (N) and invasive ductal carcinoma GII (Ca) were separated by SDS-PAGE and stained with Coomassie.
Lanes 1, 12, and 13: molecular weight standard and proteins extracts of MCF7 cells and an ovarian tumor, respectively. Asterisks indicate the
position of NUCKS band. Mr: relative molecular weight. The band of linker histone H1.4 (arrow), a highly abundant housekeeping protein,
serves a “gel loading” control. Its intensity is similar in lanes of normal breast, IDC, and MCF7 cells lysates. Identity of the H1.4 band was
conﬁrmed by mass spectrometry (Figure 1).
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Figure 2: Speciﬁcity of the antibodies elicited against NUCKS’ peptide: Puriﬁed NUCKS ((a) lanes 2–4), HClO4-extracts invasive ductal
carcinoma GII (Ca in (b): lanes 5 and 7) and MCF 7 cells ((b): lanes 6 and 8), and SDS-total lysates of normal breast (N: lanes 9, 10, 13, 14)
and invasive ductal carcinoma GII (Ca in (c): lanes 11, 12, 15, 16) each matching the same patient (c) were separated by SDS-PAGE, blotted
onto nitrocellulose and incubated with aﬃnity puriﬁed anti-NUCKS antibodies. Lane 4: the antibodies were preincubated with the peptide
used for antibody production and puriﬁcation. Total protein was stained on blots with Amido Black (lanes 1, 2, 5, 6, and 9–12).
4. Discussion
Until now NUCKS was studied in detail using a variety
of biochemical and cell biological methods [1, 2, 17, 18].
However,theseanalysesdidnotcorrelatewiththeoccurrence
of the protein in particular type of cancer and/or type of
cells. In this study the occurrence of NUCKS in human
breast cancer was studied. Using the proteomic approach
we demonstrated that NUCKS is overexpressed in tumor
cells. Histochemical analyses revealed positive staining for
NUCKS with diﬀerent frequencies. The observed expression
of NUCKS in cancer cells was found in all examined cases.
There are some unpublished reports conﬁrming NUCKS
presentation in both cellular compartments, that is, nucleiJournal of Biomedicine and Biotechnology 5
Figure 3: Occurrence of NUCKS in invasive ductal carcinoma, G
III. The positive reaction was found in majority of tumor cells with
prevalenceofnuclearstaining(arrowsandbrowncolor).Thenuclei
negative for NUCKS are stained blue or dark blue. ABC method.
Magniﬁcation 200x, inset 40x.
Figure 4: Occurrence of NUCKS in invasive ductal carcinoma, GII.
The positive staining in this case was less frequent than that in
the case shown in Figure 3. Some cells show also faint cytoplasmic
paralleltonuclearreaction.ABCmethod.Magniﬁcation200x, inset
40x.
Table 2: Comparison of P-values between G groups.
P-value
GI versus GII .002352
GI versus GIII .000004
GII versus GIII .093116
and cytoplasm. The importance of NUCKS remains still
unknown and disputable.
NUCKS has 2 regions termed as nuclear localization
signals (NLSs) where NLS1 is assumed to be main nuclear
localization signal that binds to importin α3a n dα5i nv i t r o
Figure 5: Occurrence of NUCKS in invasive ductal carcinoma,
GI. The positive staining in this case was the least frequent
in comparison to cases of IDC GII and GIII. ABC method.
Magniﬁcation 200x, inset 40x.
Figure 6: Positive control for NUCKS. This was obtained using
positive reaction forNUCKSin lymphocytes fromaninﬂammatory
inﬁltration at the border of invasive ductal carcinoma. ABC
method. Magniﬁcation 200x.
[18]. Importin is in turn a protein which after binding with
NLS moves the other proteins into nuclei. This movement
between two compartments may probably play an important
role in some phenomena leading to protection of a cell
againstundesirablefactors.ThevariedexpressionofNUCKS
in our study may reﬂect the well-known heterogeneity of
cellsinbreastcancer,whichwasconﬁrmedforKi67reactivity
[26]. The Ki67 activity was higher in ductal cancer and lower
in mucinous and lobular carcinoma. In other studies it was
foundthatusingtheVanNuysgradingsystemofworstgrade,
the grade of tumor was not associated with either ductal
carcinoma in situ recurrence or development of invasive
disease[27].Thereisalsoevidencethatinvasivebreastcancer
is the disease with multiple cytogenetic subclones already
present in preinvasive lesions [28].6 Journal of Biomedicine and Biotechnology
Figure 7: Negative control. This was obtained by omitting the
primary antibody. The sample is from invasive ductal carcinoma,
GII. Sample is counterstained with HE. Magniﬁcation 200x.
Figure 8: Normal breast. This ﬁgure presents the fat tissue from the
IDC patient at a morphologically normal site away from the lesions
which showed no reaction to anti-NUCKS antibody. ABC method,
Magniﬁcation 200x.
Grade III tumors were found to manifest high levels
of several genes involved in regulation of gene expression
including NUCKS [1]. In our study we observed correlation
between NUCKS expression and histological grading. Statis-
ticallysigniﬁcantdiﬀerenceswerefoundbetweengroupofGI
and GII cancers and also between GI and GIII, whereas there
was no signiﬁcant diﬀerence between groups GII and GIII.
T h eN U C K Sw a sr e p o r t e dt ol o c a l i z ei nb o t hp r o -
liferating and nonproliferating cells: positive staining for
NUCKS was found in our study in endothelial cells and
lymphocytes. Since endothelial cells and lymphocytes belong
to the relatively fast growing cells or at least they show high
metabolism, overexpression of NUCKS is probably related to
high levels of transcription.
In our study the positive staining was mainly observed
in nuclei of tumor cells and nuclei of normal cells. Mixed
nuclear and cytoplasmic reaction, which was seen in cells of
IDC, may reﬂect known distribution of NUCKS throughout
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Mean
SD
1.96∗SD
Figure 9: Posthoc test results of the least signiﬁcant diﬀerences,
LSD,betweendiﬀerentgroupsofcancerwithregardtograding(axis
X-groups, axis Y-fractions of stained cells).
the cytoplasm in mitotic cells whereas nuclear localization of
NUCKS is connected with telophase of cellular cycle [18].
Previously, the expression of the high-mobility group
protein gene hmgA2 and its protein as a possible marker
detectingmalignantgrowthofthyroidtumorswasused[15].
Whereas HMGA2 is highly expressed in most embryonic tis-
sues,itsexpressioninadulttissuesisverylow.However,reac-
tivation of expression was described for various malignant
tumors and correlated with aggressiveness of tumors. Since
HMGA2 expression alone allowed to distinguish between
benign and malignant thyroid tumors with sensitivity of
95.9% and speciﬁcity 93.9%, we assume that by similarities
betweenHMGAsandNUCKSthelatteraswellmightbeused
as a marker in histological evaluation of tissues. NUCKS was
previously reported to be expressed in breast, for example,
in lobular carcinoma, and ovarian cancers as a part of a
module containing at least six members that are believed to
be involved in either transcriptional regulation or ubiquitin
proteasome pathway [29].
Recently, the elevated expression of DYRK3, NUCKS,
COX-2, and translin and tubulin-α4 genes, which are
involved in proliferation and inhibition of apoptosis and cell
movement, was found to be associated with high-invasive
phenotype in mouse lung adenocarcinoma cell strains
[30]. Statistically signiﬁcant increase in the expression of
transcripts for tubulin-α4, COX-2, DYRK3, and translin was
associated there with ampliﬁcation of mouse chromosome 1.
The NUCKS protein was increased in the majority of the cell
strains [30].
In conclusion, it has to be emphasized that further
studies are needed to determine a role of NUCKS in human
cancer and that this work provides only early insights in
the abundant occurrence of the protein in breast cancer.
The future work also should pay additional attention in
elucidating potential functions of speciﬁc posttranslationalJournal of Biomedicine and Biotechnology 7
modiﬁcations of NUCKS [19] in etiology and progression of
the disease.
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